Clear All
11765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
16729-0240-03 16729-0240 FOSAPREPITANT Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Oct 22, 2020 In Use
68180-0690-01 68180-0690 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sep 25, 2020 Jan 31, 2024 No Longer Used
71288-0418-10 71288-0418 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov 15, 2019 Mar 30, 2023 No Longer Used
00591-4385-79 00591-4385 fosaprepitant Fosaprepitant 150.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sep 19, 2019 In Use
72205-0083-01 72205-0083 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous May 12, 2020 In Use
63323-0972-10 63323-0972 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sep 5, 2019 In Use
68001-0517-36 68001-0517 fosaprepitant fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug 23, 2021 Jul 31, 2024 No Longer Used
00338-0008-01 00338-0008 Fosaprepitant Dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sep 5, 2019 In Use
72603-0106-01 72603-0106 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sep 5, 2019 Oct 1, 2022 No Longer Used
67457-0889-10 67457-0889 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sep 5, 2019 In Use
45629-0089-01 45629-0089 Tivozanib FOTIVDA 0.89 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Mar 10, 2021 In Use
45629-0134-01 45629-0134 Tivozanib FOTIVDA 1.34 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Mar 10, 2021 In Use
83831-0121-04 83831-0121 Cyclophosphamide Frindovyx 2.0 g/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
83831-0120-02 83831-0120 Cyclophosphamide Frindovyx 1.0 g/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
83831-0119-01 83831-0119 Cyclophosphamide Frindovyx 500.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
63020-0210-21 63020-0210 Fruquintinib Fruzaqla 1.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov 8, 2023 In Use
63020-0225-21 63020-0225 Fruquintinib Fruzaqla 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov 8, 2023 In Use
83257-0005-41 83257-0005 Pegfilgrastim-jmdb Fulphila 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Oct 1, 2023 In Use
67457-0833-06 67457-0833 Pegfilgrastim Fulphila 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Jul 9, 2018 May 31, 2026 In Use
70710-1688-08 70710-1688 fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec 14, 2021 In Use
68001-0522-85 68001-0522 Fulvestrant FULVESTRANT 250.0 mg/5mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Oct 29, 2021 In Use
62332-0650-05 62332-0650 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec 22, 2022 In Use
68001-0626-85 68001-0626 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Jan 17, 2025 In Use
00143-9022-02 00143-9022 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Feb 10, 2022 In Use
16729-0436-30 16729-0436 Fulvestrant FULVESTRANT 250.0 mg/5mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Jan 21, 2021 In Use

Found 11765 results — Export these results